Nephron Research upgraded Bruker (BRKR) to Hold from Sell.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- Morning Movers: Kenvue surges, Kimberly-Clark sinks after tie up
- Bruker cuts FY25 EPS view to $1.85-$1.90 from $1.95-$2.05, consensus $1.94
- Bruker reports Q3 EPS 45c, consensus 33c
- BRKR Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Bruker Inc: Promising Product Launches Amid Market Uncertainties Lead to Hold Rating